Based upon the previous success with immunotherapy for patients with recurring leukemia, Seattle Children’s Research Institute announced the opening of patient enrollment for its new FDA authorized clinical trial designed to induce remission in children suffering from Neuroblastoma, one of the deadliest forms of childhood cancer.
The Phase 1 trial is one of the first to target pediatric solid tumors using cellular immunotherapy. According to Dr. Julie Park at Seattle Children’s, solid tumors are especially challenging, but they have encouraging research suggesting this treatment can be used to safely treat Neuroblastoma.
Participants in the ENCIT-01 trial will be children or adolescents with Neuroblastoma who have responded poorly to standard treatments of chemotherapy and/or radiation. Typically, these children have less than a 10% chance of surviving. These trials are aimed at giving them and their families hope. Make Some Noise continues to support this groundbreaking research.
